AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential.
p97/VCP, a member of the AAA-ATPase super family, has been associated with a wide variety of essential cellular protein pathways com prising: (i) nuclear envelope reconstruction, (ii) cell cycle, (iii) Golgi reassembly, (iv) suppression of apoptosis and (v) DNA-damage response [1-6]. In addition, vasolin-containing protein (VCP) dislodges the ubiquitinated proteins from the endoplasmic reticulum (ER) and chaperones them to the cytosol for proteasomal degradation by endoplasmic reticulum-associated degradation (ERAD) [7]. The interactions of VCP in the endoplasmic reticulum-associated degradation (ERAD) pathway determine the substrate selection for proteasomal degradation. Moreover, the interaction with VCP is also required for the ubiquitination of substrate. VCP is phosphorylated by the master cellular kinase, Akt as a mechanism to regulate ERAD [8]. These multiple interactions in protein degradation pathways points to central role of VCP in misfolded protein degradation. VCP has a polyglutamine and ubiquitin-binding capacity and is involved in proteasomal degradation, cytosolic aggregation and processing of polyQ and polyUb aggregates in neurodegenerative and other misfolded protein diseases [9, 10]. Mutations in VCP gene are also linked to a protein deposition disorder, IBMFD [11]. We propose VCP as a therapeutic target for diseases caused by cytosolic protein aggregation or degradation of misfolded protein. We predict that selective interference of VCP interaction(s) with aberrant protein or its ERAD function will be an effective therapeutic site to rescue functional misfolded protein in diseases like cystic fibrosis and alpha-1-trypsin deficiency. The control of VCP expression is also proposed to be a potential therapeutic target in ex-polyQ-induced neurodegenerative diseases [12]. The further functional characterization of VCP and associated proteins in these diseases will help in designing of selective therapeutics.
Vij
Neeraj
N
Division of Pediatric Respiratory Sciences & Institute of NanoBioTechnology, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. nvij1@jhmi.edu
D000251:Adenosine Triphosphatases / Q000737:chemistry / Q000235:genetics / Q000502:physiology* / Q000627:therapeutic use*; D000818:Animals; D018797:Cell Cycle Proteins / Q000737:chemistry / Q000235:genetics / Q000502:physiology* / Q000627:therapeutic use*; D004721:Endoplasmic Reticulum / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D008954:Models, Biological; D008967:Molecular Biology; D015394:Molecular Structure; D046912:Multiprotein Complexes; D017510:Protein Folding; D015398:Signal Transduction; D013312:Stress, Physiological; D000074405:Valosin Containing Protein
D018797:Cell Cycle Proteins; D046912:Multiprotein Complexes; D000251:Adenosine Triphosphatases; C000614178:VCP protein, human; D000074405:Valosin Containing Protein
Nature. 1993 Sep 30;365(6445):459-62
8413590
Nat Cell Biol. 2005 Aug;7(8):766-72
16056268
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14132-8
16186510
Biochem Soc Trans. 2008 Feb;36(Pt 1):105-8
18208395
Nat Cell Biol. 2001 Dec;3(12):1086-91
11781570
Mol Biol Cell. 2003 Jan;14(1):262-73
12529442
EMBO J. 2006 Jul 26;25(14):3357-66
16810319
Mol Cell Biol. 2002 Jan;22(2):626-34
11756557
Mol Biol Cell. 2008 Apr;19(4):1328-36
18216283
J Biol Chem. 1998 Feb 6;273(6):3562-73
9452483
Arch Biochem Biophys. 2007 Jun 1;462(1):62-73
17493577
Am J Respir Cell Mol Biol. 2008 Feb;38(2):176-84
17709599
Mol Cancer Ther. 2002 Dec;1(14):1243-53
12516957
Nature. 2001 Dec 6;414(6864):652-6
11740563
J Biol Chem. 2004 Dec 3;279(49):51376-85
15456787
Nature. 1997 Jul 3;388(6637):75-8
9214505
Cell. 1995 Sep 22;82(6):905-14
7553851
J Biol Chem. 2008 Aug 8;283(32):21926-33
18508776
Ann Surg Oncol. 2004 Feb;11(2):165-72
14761919
Am J Respir Crit Care Med. 2008 Oct 15;178(8):838-46
18635891
Mol Cell. 2005 Sep 16;19(6):829-40
16168377
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1285-93
16979136
Mol Cell. 2006 May 19;22(4):451-62
16713576
Ann Surg Oncol. 2004 Jul;11(7):697-704
15231524
Clin Cancer Res. 2003 Jan;9(1):346-54
12538487
EMBO J. 2000 May 15;19(10):2181-92
10811609
Trends Genet. 1998 Oct;14(10):396-402
9820028
Cell Death Differ. 2002 Mar;9(3):264-73
11859409
Cell. 2006 Aug 11;126(3):571-82
16901789
Cell. 2003 Dec 12;115(6):727-38
14675537
J Biol Chem. 2007 Nov 23;282(47):33908-14
17872946
Nat Genet. 2004 Apr;36(4):377-81
15034582
Cell. 1998 Mar 6;92(5):603-10
9506515
Genes Cells. 2007 Jul;12(7):889-901
17584300
J Biol Chem. 2004 Oct 29;279(44):45676-84
15331598
Mol Cancer Ther. 2006 Sep;5(9):2251-60
16985059
Mol Biol Cell. 2000 Aug;11(8):2529-42
10930451
Trends Biochem Sci. 2001 Oct;26(10):619-24
11590015
Ann Neurol. 2005 Mar;57(3):457-61
15732117
Biochim Biophys Acta. 2008 Jul;1783(7):1418-35
18284922
J Biol Chem. 2006 Jun 23;281(25):17369-17378
16621797
Am J Respir Cell Mol Biol. 2007 Jun;36(6):706-14
17272822
Cell Death Differ. 2001 Oct;8(10):977-84
11598795
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13637-42
11087817
J Biol Chem. 2005 Sep 9;280(36):31870-81
16027165
Cancer Res. 2006 Apr 1;66(7):3773-81
16585204
J Biochem. 2005 Feb;137(2):115-9
15749824
Jpn J Cancer Res. 2002 Mar;93(3):296-304
11927012
FEBS Lett. 2006 Jan 23;580(2):474-8
16386250
Mol Biol Cell. 2003 Oct;14(10):4221-9
12937274
EMBO Rep. 2001 May;2(5):423-30
11375935
Nat Cell Biol. 2001 Aug;3(8):740-4
11483959
Mol Biol Cell. 2004 Sep;15(9):4125-35
15215312